AMGN vs BIIB stock comparison
Amgen vs. Biogen · data as of November 13, 2026
Amgen (AMGN) has a market value of about $251.9B, Biogen (BIIB) about $37.5B. Over their latest twelve months Amgen had revenue of $38.9B and Biogen $10.3B.
On our five checks Amgen scores higher: 2.4 out of 5 (weak) against 1.8 (weak).
By area, the stronger company is Biogen on value; Amgen on future growth; Amgen on track record; Biogen on financial health; Amgen on shareholder returns.
Amgen is cheaper on earnings (P/E 27.0 vs. 109.2).
Amgen leads on 16 of the compared lines and Biogen on 8.
Side by side
| AMGN | BIIB | |
|---|---|---|
| Size and price | ||
| Market cap | $251.9B | $37.5B |
| Share price | $465.67 | $253.40 |
| Score | ||
| Overall score (of 5) | 2.4 | 1.8 |
| Value | 0 | 1 |
| Future growth | 3 | 2 |
| Track record | 3 | 1 |
| Financial health | 2 | 4 |
| Shareholder returns | 4 | 1 |
| Valuation | ||
| P/E (TTM) | 27.0 | 109.2 |
| Forward P/E | 19.5 | 17.4 |
| Price / free cash flow | 26.3 | 18.1 |
| Price / sales | 6.5 | 3.6 |
| EV / EBITDA | 17.1 | 26.7 |
| PEG | 9.18 | — |
| DCF value vs. price | −26% | −33% |
| Business | ||
| Revenue | $38.9B | $10.3B |
| Net income | $9.4B | $348M |
| Free cash flow | $9.6B | $2.1B |
| Net margin | 24.1% | 3.4% |
| Gross margin (5-yr avg.) | 69.9% | 76.9% |
| ROIC (5-yr avg.) | 13.5% | 9.2% |
| Growth | ||
| Revenue growth (1 yr) | 10.0% | 2.2% |
| Revenue growth (5 yrs, per year) | 7.6% | -6.0% |
| EPS growth (5 yrs, per year) | 2.9% | -18.7% |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$40.8B | -$6.1B |
| Dividend yield | 2.16% | None |
| Shareholder yield | 2.2% | 0.0% |
| Analysts | ||
| Upside to average target | −7% | +6% |
| Consensus rating | Hold | Buy |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: AMGN TTM to September 30, 2026, BIIB TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, Amgen or Biogen?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Amgen scores 2.4 out of 5 and Biogen 1.8; the table shows where each one is stronger.
Is Amgen cheaper than Biogen?
On trailing earnings, Amgen trades at a P/E of 27.0 and Biogen at 109.2, so Amgen is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Which grows faster, Amgen or Biogen?
Over five years Amgen grew revenue about 7.6% a year and Biogen about -6.0% a year.
Which pays a higher dividend?
Amgen yields 2.16% and Biogen nothing (no dividend).
Full Amgen analysis → Full Biogen analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.